Overview

Mycophenolate Mofetil (MMF) for Treatment of Chronic Graft-versus-host Disease (GVHD)

Status:
Terminated
Trial end date:
2008-09-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Mycophenolate mofetil added to immunosuppressive treatment regimens may be effective in treating newly diagnosed chronic graft-versus-host disease caused by stem cell transplantation. It is not yet known whether immunosuppressive treatment regimens are more effective with or without mycophenolate mofetil in treating chronic graft-versus-host disease. PURPOSE: This randomized phase III trial is studying whether the addition of mycophenolate mofetil improves the efficacy of immunosuppressive treatment regimens in patients with newly diagnosed chronic graft-versus-host disease.
Phase:
Phase 3
Details
Lead Sponsor:
Martin, Paul
Collaborator:
National Cancer Institute (NCI)
Treatments:
Mycophenolate mofetil
Mycophenolic Acid